Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· October 25, 2025

North America Set to Cut Rates as Rest of G-7 Looks On

View original at finance.yahoo.com
North America Set to Cut Rates as Rest of G-7 Looks On The Marriner S. Eccles Federal Reserve building in Washington, DC…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Euro zone probably eked out growth of just 0.1% during the third quarter

    80% confidence
  • Fed Chair Jerome Powell will likely characterize the cut as insurance against downside risks to employment

    80% confidence
  • Policymakers have little reason to adjust their outlook from September, keeping another cut on the table for December

    80% confidence
  • Colombia should have lower interest rates to bolster growth

    80% confidence
  • China's official PMIs likely to show factory sentiment improving only marginally despite fiscal and credit support

    80% confidence
  • Headline inflation of 2.4% and core measures averaging 3.15% are contained enough to justify delivering aid to the tariff-bruised economy

    80% confidence
  • France's expansion forecast to have slowed slightly in the third quarter, to 0.2%

    80% confidence
  • Mexico flash reading may show negative quarterly and annual readings as declines in manufacturing outweigh resilient household consumption

    80% confidence
  • Given unanchored expectations, a rate hike is on the table

    80% confidence
  • Alternative data suggest continued downside risks to employment despite government shutdown delaying official data

    80% confidence
  • Consumer confidence retreated for a third straight month amid anxiety about jobs

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com